RE:RE:RE:RE:RE:New Press Release - Theralase(R) Release's 1Q2024 Financial Statements Overall the data is very strong IMO. We are probably going to see in the end 35-40% CR at 45 days. If we can maintain 25-30% CR at 24 months, we will be looking way above the competition. Only 33 patients got a 2nd treatment ( maintenance treatment) out of 62. I don't know why not all 62 patients received a 2nd treatment? It seems no one yet received a 3rd treatment, unless not specified but I highly doubt it. It is subject to the discretion of the investigator. Perhaps they may opt a possible 3rd treatment for newly treated patients? Overall optimistic, just hope they get to submit BTD sooner than later. Hopefully before end of June, but we are definitely close.
Donein25 wrote: But no mention of 2 year data...which seems to be the new benchmark for FDA. Also, it looks to me like CR% are decreasing accross the board. Can someone confirm that impression? Also, last October they announced Optimization to include additional treatment for recurrence. Why has there been no data on these retreatments? One would think re-reatment would be driving CR % higher.